N/A
Completed N=51
Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients
Source: ClinicalTrials.gov NCT01933984 ↗Enrolled (actual)
51
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: ∆Raw (the Difference Between Measured and Target Airway Resistance) — 9; 44 percentage of relative Raw deviation
Summary
This study evaluates whether individualized dosing schedule of inhaled bronchodilator is more effective than fixed dosing in reducing airway resistance of intubated COPD patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY ∆Raw (the Difference Between Measured and Target Airway Resistance) |
9; 44 | — |
| PRIMARY Rapidity of ∆Raw Change |
-3; 0.4 | — |
| SECONDARY Ventilator-free Days From Day 1 to 28 |
19; 22 | — |
| SECONDARY The Participants of Breathing Without Assistance by Day 28 |
19; 22 | — |
| SECONDARY Number of Episode of Nosocomial Pneumonia |
0; 0 | — |
| SECONDARY Number of Total Puff of Rescue Short-acting Bronchodilator |
0; 0 | — |
| SECONDARY Numbers of Episode of Drug-related Adverse Effect |
0; 0 | — |
| SECONDARY Mortality Rate |
35; 40 | — |
Eligibility Criteria
Inclusion Criteria
- chronic obstructive pulmonary disease
- acute respiratory failure under ventilator support for less than 72 hours
- endotracheal tube inserted
Exclusion Criteria
- confirmed asthma
- Acute Physiology and Chronic Health Evaluation II score over 35
- a co-morbidity of septic shock
Data sourced from ClinicalTrials.gov (NCT01933984). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.